Hu Xiaoli, Yu Jiangtao, Lin Zixia, Feng Renqian, Wang Zhi-Wei, Chen Gang
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Cell Death Discov. 2021 Jun 21;7(1):163. doi: 10.1038/s41420-021-00532-x.
Emerging evidence demonstrates that WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) participates into carcinogenesis and tumor progression. In this review article, we will describe the association between dysregulated WWP1 expression and clinical features of cancer patients. Moreover, we summarize the both oncogenic and tumor suppressive functions of WWP1 in a variety of human cancers. Furthermore, we briefly describe the downstream substrates of WWP1 and its upstream factors to regulate the expression of WWP1. Notably, targeting WWP1 by its inhibitors or natural compounds is potentially useful for treating human malignancies. Finally, we provide the perspectives regarding WWP1 in cancer development and therapies. We hope this review can stimulate the research to improve our understanding of WWP1-mediated tumorigenesis and accelerate the discovery of novel therapeutic strategies via targeting WWP1 expression in cancers.
新出现的证据表明，含WW结构域的E3泛素蛋白连接酶1（WWP1）参与致癌作用和肿瘤进展。在这篇综述文章中，我们将描述WWP1表达失调与癌症患者临床特征之间的关联。此外，我们总结了WWP1在多种人类癌症中的致癌和抑癌功能。此外，我们简要描述了WWP1的下游底物及其上游调节WWP1表达的因子。值得注意的是，通过其抑制剂或天然化合物靶向WWP1可能对治疗人类恶性肿瘤有用。最后，我们提供了关于WWP1在癌症发展和治疗方面的观点。我们希望这篇综述能够激发相关研究，以增进我们对WWP1介导的肿瘤发生的理解，并通过靶向癌症中WWP1的表达加速新型治疗策略的发现。
